dental management of bleeding disorder...
TRANSCRIPT
![Page 1: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/1.jpg)
Dental Management of Bleeding Disorder Patients
1
![Page 2: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/2.jpg)
Bleeding disordersSummary of mechanisms of coagulation following tissue injury
Injury to blood vessel
Vessel contraction Collagen exposure Tissuethromboplastin release
intrinsic p/w extrinsic p/w
Platelet reaction Activation of coagulation
loose platelet thrombinaggregation
fibrin
Temporary haemostatic plug definitive haemostatic plug
fibrinolytic system
2
![Page 3: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/3.jpg)
Clotting mechanism
Intrinsic pathway Extrinsic pathwayCollagen Tissue thromboplastin
XIIXI
IX VIIVIII
X fibrinogen IV Lipids
Ca++Prothrombin II thrombin
Fibrin (loose)
Plasmin fibrinolysis Fibrin (tight)
3
![Page 4: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/4.jpg)
Coagulation cascade
Vitamin K dependant factors
XIIa
IIa
Intrinsic system (surface contact)
XII
XI XIa
Tissue factor
IX IXa VIIa VII
VIII VIIIa
Extrinsic system (tissue damage)
X
V Va
II
Fibrinogen Fibrin
(Thrombin)IIa
Xa
4
![Page 5: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/5.jpg)
Laboratory Evaluation of the Coagulation Pathways
Partial thromboplastin time(PTT)
Prothrombin time(PT)
Intrinsic pathway Extrinsic pathway
Common pathwayThrombin timeThrombin
Surface activating agent(Ellagic acid, kaolin)
PhospholipidCalcium
ThromboplastinTissue factorPhospholipid
Calcium
Fibrin clot
5
![Page 6: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/6.jpg)
Protocol for investigation of a clotting disorders
History Take blood Laboratory investigation
APTT Normal APTT
Prolong APTT Assay factors VIII, IX
PT
Prolong PT Assay factor II, V,VII, X and fibrinogen
6
![Page 7: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/7.jpg)
Contd.Laboratory testsEssential tests included: Bleeding time ( 5-10 min.) Platelet count ( 100,000-400,000/mm3
APTT ( 25-40 sec.) Prothrombin time ( 10-15 sec.) Serum for blood grouping and cross matching
7
![Page 8: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/8.jpg)
Laboratory findings in clotting disorders
Haemiphilia A,B, factor XI, XII deficiency APTT Anticoagulant therapy, obstructive
jaundice, vit.K deficiency, PT,APTTFactor V, X deficiency
Heparin therapy PT, APTT DIC, liver disease PT, APTT Factor VII deficiency PT *INR = International Normalized Ratio INR = (PTR)ISI , ISI= International Sensitivity Index
PTR= patient prothrombin time/reference control plasma
8
![Page 9: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/9.jpg)
Disseminated Intravascular Coagulation (DIC)Mechanism
Systemic activationof coagulation
Intravasculardeposition of fibrin
Depletion of plateletsand coagulation factors
BleedingThrombosis of smalland midsize vesselswith organ failure
9
![Page 10: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/10.jpg)
Pathophysiology of disseminated intravascular coagulation - ( DIC )Robbins 10
![Page 11: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/11.jpg)
Common clinical conditionsassociated with DIC
Sepsis
Trauma◦ Head injury
◦ Fat embolism
Malignancy
Obstetrical complications◦ Amniotic fluid embolism◦ Abruptio placentae
Vascular disorders
Reaction to toxin (e.g. snake venom, drugs)
Immunologic disorders◦ Severe allergic reaction◦ Transplant rejection
11
![Page 12: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/12.jpg)
DICTreatment approaches
Treatment of underlying disorder
Anticoagulation with heparin
Platelet transfusion
Fresh frozen plasma
12
![Page 13: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/13.jpg)
Hematological problemsManagement of patient with a coagulopathy
Defer surgery until a hematologist is consulted about the patient’s management
Obtain baseline coagulation tests as indicated ( prothrombin time, partial thromboplastin time, bleeding time, platelet count and a hepatitis screen
Schedule the patients in a manner that allows surgery soon after any coagulation correcting measures have been taken ( after platelet transfusion, factor replacement, or aminocaproic acid administration)
13
![Page 14: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/14.jpg)
Contd.
Augment clotting during surgery with the use of topical coagulation promoting substance, sutures, and well place pressure packs
Monitor the wound for 2 hours to ensure that good initial clot forms
Instruct patient in ways to prevent dislodgement of the clot and in what to do should bleeding restarts
Avoid prescribing NSAIDs
Take hepatitis precautions during surgery
14
![Page 15: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/15.jpg)
Management of patient who is therapeutically anticoagulated
Patients receiving aspirin or other platelet inhibiting drugs
Consult the patient’s physician to determine the safety of stopping the anticoagulant drug for several days
Defer surgery until the platelet inhibiting drugs have been stopped for 5 days
Take extra measures during and after surgery to help promote clot formation and retention
Restart drug therapy on the day after surgery if no bleeding is present
15
![Page 16: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/16.jpg)
Contd.
Patients receiving warfarin (coumadin)
Consult the patient physician to determine the safety of allowing the PT to fall to 1.5 INR for few days
Obtain baseline PT
If PT is 1 to 1.5 INR , proceed with surgery
16
![Page 17: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/17.jpg)
Contd. If the PT is more than 1.5 INR, stop warfarin
approximately 2 days before surgery
Check the PT daily and proceed with the surgery on the day when the PT falls to 1.5 INR
Take extra measures during and after surgery, to help promote clot formation and retention
Restart warfarin on the day of surgery
17
![Page 18: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/18.jpg)
Contd.
Antibiotics which are safe with Coumadin
Prolong courses of any antibiotic can effect the intestinal flora, alter vitamin K synthesis and prolong INR.
Make a course of antibiotic administration as short as possible.
18
![Page 19: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/19.jpg)
Contd.
Among the antibiotics commonly prescribed for treatment of dental infection:
Tetracycline is contraindicated.
Erythromycin, clarithromycin, metronidazole, ciprofloxacin, ofloxacin and levofloxacin interact with coumadin and should be avoided.
Safer antibiotics include penicillins, cephalosporins, clindamycin and azithromycin.
19
![Page 20: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/20.jpg)
Contd.
Azithromycin is an interesting macrolide that does not interfere with cytochrome p450 and less effect on anticoagulation therapy.
20
![Page 21: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/21.jpg)
Contd.
Safer analgesics: Aspirin and NSAIDs should be avoided.
Acetaminophen can interact with Coumadin to a finite extent. Several doses of acetaminophen can increase the INR of patients on stable doses of Coumadin.
Safer analgesics include codeine(methylmorphine) and codeine derivatives, lower doses of acetaminophen component, meperidine (pethidine) or meperidine plus promethazine (phenergan, long lasting hyponotic).
21
![Page 22: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/22.jpg)
Contd.
Patients receiving heparin
Consult patient’s physician to determine the safety of stopping heparin for the perioperative period
Defer surgery until at least 6 hours after the heparin is stopped
Restart heparin once a good clot has formed
22
![Page 23: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/23.jpg)
Disorders of Platelets and Platelet Transfusion
23
![Page 24: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/24.jpg)
Sites of bleeding in thrombocytopenia
Skin and mucous membranes◦ Petechiae◦ Ecchymosis◦ Hemorrhagic vesicles◦ Gingival bleeding and epistaxis
Menorrhagia Gastrointestinal bleeding Intracranial bleeding
24
![Page 25: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/25.jpg)
Petechiae
Do not blanch with pressure(cf. angiomas)
Not palpable(cf. vasculitis)
25
![Page 26: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/26.jpg)
Classification of platelet disorders
Quantitative disorders
◦ Abnormal distribution◦ Dilution effect◦ Decreased production
◦ Increased destruction
Qualitative disorders
◦ Inherited disorders (rare)◦ Acquired disorders Medications Chronic renal failure Cardiopulmonary bypass
26
![Page 27: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/27.jpg)
Acquired thrombocytopenia with shortened platelet survival
Associated with bleeding
◦ Immune-mediated thrombocytopenia (ITP)
◦ Most drug-induced thrombocytopenias
◦ Most others
Associated with thrombosis
◦ Thrombotic thrombocytopenic purpura
◦ DIC◦ Trousseau’s syndrome◦ Heparin-associated
thrombocytopenia
27
![Page 28: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/28.jpg)
Approach to the thrombocytopenic patient History◦ Is the patient bleeding?◦ Are there symptoms of a secondary illness? (neoplasm, infection,
autoimmune disease)◦ Is there a history of medications, alcohol use, or recent
transfusion?◦ Are there risk factors for HIV infection?◦ Is there a family history of thrombocytopenia?◦ Do the sites of bleeding suggest a platelet defect?
Assess the number and function of platelets◦ CBC with peripheral smear◦ Platelet function study
28
![Page 29: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/29.jpg)
Platelet function screen Replaces the bleeding time as a test of
platelet function
PFA-100; ordered as “platelet function screen”
Blue top tube
Measures the time it takes for blood to block membrane coated with either collagen/epinephrine or collagen/ADP
29
![Page 30: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/30.jpg)
Platelet transfusions Source◦ Platelet concentrate (Random donor)
Each donor unit should increase platelet count ~10,000 /µl◦ Pheresis platelets (Single donor)
Storage◦ Up to 5 days at room temperature
“Platelet trigger”◦ Bone marrow suppressed patient (>10-20,000/µl)◦ Bleeding/surgical patient (>50,000/µl)
30
![Page 31: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/31.jpg)
Platelet transfusions - complications
Transfusion reactions◦ Higher incidence than in RBC transfusions◦ Related to length of storage/leukocytes/RBC mismatch◦ Bacterial contamination
Platelet transfusion refractoriness◦ Alloimmune destruction of platelets (HLA antigens)◦ Non-immune refractoriness
Microangiopathic hemolytic anemia Coagulopathy Splenic sequestration Fever and infection Medications (Amphotericin, vancomycin, ATG,
Interferons)31
![Page 32: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/32.jpg)
Laboratory Evaluation of BleedingOverview
CBC and smear Platelet count ThrombocytopeniaRBC and platelet morphology TTP, DIC, etc.
Coagulation Prothrombin time Extrinsic/common pathwaysPartial thromboplastin time Intrinsic/common pathwaysCoagulation factor assays Specific factor deficiencies50:50 mix Inhibitors (e.g., antibodies)Fibrinogen assay Decreased fibrinogenThrombin time Qualitative/quantitative
fibrinogen defectsFibrinolysis (DIC)
Platelet function von Willebrand factor vWDBleeding time In vivo test (non-specific)Platelet function analyzer (PFA) Qualitative platelet disorder
and vWDPlatelet function tests Qualitative platelet disorder
32
![Page 33: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/33.jpg)
Adjunctive therapy forbleeding disorders
33
![Page 34: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/34.jpg)
Adjunctive drug therapy for bleeding
Fresh frozen plasmaCryoprecipitateEpsilon-amino-caproic acid (Amicar)DDAVPRecombinant human factor VIIa (Novoseven)
34
![Page 35: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/35.jpg)
Fresh frozen plasma
Content - plasma (decreased factor V and VIII) Indications◦ Multiple coagulation deficiencies (liver disease, trauma)◦ DIC◦ Warfarin reversal◦ Coagulation deficiency (factor XI or VII)
Dose (225 ml/unit)◦ 10-15 ml/kg
Note◦ Viral screened product◦ ABO compatible
35
![Page 36: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/36.jpg)
Cryoprecipitate
Prepared from FFP Content◦ Factor VIII, von Willebrand factor, fibrinogen
Indications◦ Fibrinogen deficiency◦ Uremia◦ Von Willebrand disease
Dose (1 unit = 1 bag)◦ 1-2 units/10 kg body weight
36
![Page 37: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/37.jpg)
Aminocaproic acid (Amicar)
Mechanism◦ Prevent activation plaminogen -> plasmin
Dose◦ 50mg/kg po or IV q 4 hr
Uses◦ Primary menorrhagia◦ Oral bleeding◦ Bleeding in patients with thrombocytopenia◦ Blood loss during cardiac surgery
Side effects◦ GI toxicity◦ Thrombi formation
37
![Page 38: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/38.jpg)
Desmopressin (DDAVP)
Mechanism◦ Increased release of VWF from endothelium
Dose◦ 0.3µg/kg IV q12 hrs◦ 150mg intranasal q12hrs
Uses◦ Most patients with von Willebrand disease◦ Mild hemophilia A
Side effects◦ Facial flushing and headache◦ Water retention and hyponatremia
38
![Page 39: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/39.jpg)
Recombinant human factor VIIa(rhVIIa; Novoseven)
Mechanism◦ Activates coagulation system through extrinsic pathway
Approved Use◦ Factor VIII inhibitors in hemophiliacs
Dose: (1.2 mg/vial)◦ 90 µg/kg q 2 hr ◦ “Adjust as clinically indicated”
39
![Page 40: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/40.jpg)
Recombinant human factor VIIain non-approved settings
Surgery or trauma with profuse bleeding◦ Consider in patients with excessive bleeding without apparent
surgical source and no response to other components
◦ Dose: 50-100ug/kg for 1-2 doses
◦ Risk of thrombotic complications not well defined
Anticoagulation therapy with bleeding◦ 20ug/kg with FFP if life or limb at risk; repeat if needed for bleeding
40
![Page 41: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/41.jpg)
Approach to bleeding: Summary
Identify and correct any specific defect of hemostasis
Use non- transfusional drugs whenever possible
RBC transfusion for surgical procedures or large blood loss
41
![Page 42: Dental Management of Bleeding Disorder Patientsmohs.gov.mm/ckfinder/connector?command=Proxy&lang=en&... · Bleeding Disorder Patients 1. Bleeding disorders Summary of mechanisms of](https://reader034.vdocument.in/reader034/viewer/2022042806/5f70ec574248ee05db2abea3/html5/thumbnails/42.jpg)
42